L
Lisa Anderson
Researcher at Queensland University of Technology
Publications - 19
Citations - 828
Lisa Anderson is an academic researcher from Queensland University of Technology. The author has contributed to research in topics: Compound heterozygosity & Exome sequencing. The author has an hindex of 10, co-authored 18 publications receiving 411 citations. Previous affiliations of Lisa Anderson include University of Queensland.
Papers
More filters
Journal ArticleDOI
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Glen A Kennedy,Glen A Kennedy,Antiopi Varelias,Slavica Vuckovic,Laetitia Le Texier,Kate H. Gartlan,Ping Zhang,Gethin P. Thomas,Lisa Anderson,Glen M. Boyle,Nicole Cloonan,Justine Leach,Justine Leach,Elise Sturgeon,Elise Sturgeon,Judy Avery,Judy Avery,Stuart D. Olver,Mary Lor,Ashish Misra,Cheryl Hutchins,A. James Morton,Simon Durrant,Elango Subramoniapillai,Jason Butler,Cameron Curley,Kelli P. A. MacDonald,Siok-Keen Tey,Siok-Keen Tey,Geoffrey R. Hill,Geoffrey R. Hill +30 more
TL;DR: Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways and a randomised, controlled trial assessing tocilizumab in addition to standard GVHD prophylaxis in patients is warranted.
Posted ContentDOI
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Žentelis,Denisa Foster,Peter Edward Vaillancourt,Wiggin M,Erica Lovett,van der Lee R,Jorg Hendle,A. Pustilnik,Sauder Jm,Lucas Kraft,Yuri Hwang,Robert W. Siegel,Chen J,Beverly A. Heinz,Richard E. Higgs,Kalleward N,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Davide Pellacani,Ping Xiang,de Puyraimond,Marketa Ricicova,Devorkin L,Pritchard C,O’Neill A,Dalal K,Panwar P,Dhupar H,Garces Fa,Courtney A. Cohen,John M. Dye,Kathleen E. Huie,Catherine V. Badger,Darwyn Kobasa,Darwyn Kobasa,Jonathan Audet,Jonathan Audet,Freitas Jj,Saleema Hassanali,Ina Hughes,Munoz L,Palma Hc,Bharathi Ramamurthy,Cross Rw,Cross Rw,Geisbert Tw,Geisbert Tw,Menacherry,Kumari G. Lokugamage,Borisevich,Lanz I,Lisa Anderson,Sipahimalani P,Kizzmekia S. Corbett,Lingshu Wang,Eun Sung Yang,Yanzhao Zhang,Wei Shi,Barney S. Graham,Mascola,Fernandez Tl,Carl L. Hansen,Ester Falconer,Bryan Edward Jones,Bryan C. Barnhart +67 more
TL;DR: The LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset as mentioned in this paper.
Posted ContentDOI
LY-CoV1404 potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Žentelis,Denisa Foster,Peter Edward Vaillancourt,Matthew Wiggin,Erica Lovett,Robin van der Lee,Jorg Hendle,A. Pustilnik,J. Michael Sauder,Lucas Kraft,Yuri Hwang,Robert W. Siegel,Jinbiao Chen,Beverly A. Heinz,Richard E. Higgs,Nicole Kalleward,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Davide Pellacani,Ping Xiang,Valentine de Puyraimond,Marketa Ricicova,Lindsay Devorkin,Caitlin Pritchard,Kush Dalal,Pankaj Panwar,Harveer Dhupar,Fabian A. Garces,Courtney A. Cohen,John M. Dye,Kathleen E. Huie,Catherine V. Badger,Darwyn Kobasa,Darwyn Kobasa,Jonathan Audet,Jonathan Audet,Joshua J. Freitas,Saleema Hassanali,Ina Hughes,Luis Munoz,Holly C. Palma,Bharathi Ramamurthy,Robert W. Cross,Robert W. Cross,Thomas W. Geisbert,Thomas W. Geisbert,Vineet Menacherry,Kumari Lokugamage,Viktoriya Borisevich,Iliana Lanz,Lisa Anderson,Payal Sipahimalani,Kizzmekia S. Corbett,Lingshu Wang,Eun Sung Yang,Yi Zhang,Wei Shi,Barney S. Graham,John R. Mascola,Tara L. Fernandez,Carl L. Hansen,Ester Falconer,Bryan Edward Jones,Bryan C. Barnhart +66 more
TL;DR: The LY-CoV1404 as discussed by the authors antibody is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient approximately 60 days after symptom onset.
Journal ArticleDOI
Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis
Beben Benyamin,Ji He,Qiongyi Zhao,Jacob Gratten,Fleur C. Garton,Paul Leo,Paul Leo,Zhijun Liu,Marie Mangelsdorf,Ammar Al-Chalabi,Lisa Anderson,Lisa Anderson,Tim J. Butler,Lu Chen,Xiang Ding Chen,Katie Cremin,Katie Cremin,Hong Weng Deng,Matthew S Devine,Janette Edson,Jennifer A. Fifita,Sarah Furlong,Ying Ying Han,Jessica Harris,Jessica Harris,Anjali K. Henders,Rosalind L. Jeffree,Zi-Bing Jin,Zhongshan Li,Ting Li,Mengmeng Li,Yong Lin,Xiaolu Liu,Mhairi Marshall,Mhairi Marshall,Emily P. McCann,Bryan J. Mowry,Shyuan T. Ngo,Roger Pamphlett,Shu Ran,David C. Reutens,Dominic B. Rowe,Perminder S. Sachdev,Sonia Shah,Sharon Song,Sharon Song,Li Jun Tan,Lu Tang,Leonard H. van den Berg,Wouter van Rheenen,Jan H. Veldink,Robyn H. Wallace,Lawrie Wheeler,Lawrie Wheeler,Kelly L. Williams,Jinyu Wu,Xin Wu,Jian Yang,Weihua Yue,Zong Hong Zhang,Dai Zhang,Peter G. Noakes,Ian P. Blair,Robert D. Henderson,Robert D. Henderson,Pamela A. McCombe,Peter M. Visscher,Huji Xu,Perry F. Bartlett,Matthew A. Brown,Matthew A. Brown,Naomi R. Wray,Dongsheng Fan +72 more
TL;DR: A significant association of rs10463311 spanning GPX3-TNIP1 with ALS is found and GGNBP2 was identified using gene-based analysis and summary statistics-based Mendelian randomization analysis, although further replication is needed to confirm this result.
Journal ArticleDOI
Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression
Abdulla Watad,Hannah Rowe,Tobias Russell,Qiao Zhou,Qiao Zhou,Lisa Anderson,Almas Khan,Robert Dunsmuir,Peter Loughenbury,Vishal Borse,Abhay Rao,Peter Millner,Nicola Luigi Bragazzi,Nicola Luigi Bragazzi,Howard Amital,Richard Cuhtbert,Miriam Wittmann,Miriam Wittmann,Kassem Sharif,Tony J. Kenna,Matthew A. Brown,Darren J. Newton,Charlie Bridgewood,Dennis McGonagle +23 more
TL;DR: Healthy human entheseal CD4+ and CD8- T cells exhibit regulatory characteristics and are predicted to exhibit antiviral reactivity with CD8+ T’cells expressing higher levels of transcripts suggestive of tissue residency.